Healthcare product and device company Abbott Laboratories (NYSE:ABT)
will be reporting earnings this Thursday before market open. Here’s what to look for.
The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase, signaling a definitive end to the stagnation that plagued 2023 and 2024. As of January 19, 2026, the financial
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 21.1% gain over the past six months, beating the S&P 500 by 10.6 percentage points.
As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a resilient tech economy, healthcare investors were left nursing a "double-digit hangover." In 2024,
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025 financial results that comfortably beat both internal guidance and Wall Street estimates. The Colorado-based lung diagnostics specialist reported a
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has been defined by the explosive rise of GLP-1 weight-loss drugs and the volatility of post-pandemic earnings, Abbott has successfully completed a pivot that many [...]
Date: January 9, 2026 Introduction As the global healthcare landscape undergoes a seismic shift toward personalized medicine and AI-integrated care, Medtronic plc (NYSE: MDT) stands at a critical juncture. Once viewed as a reliable but sluggish dividend aristocrat, the world’s largest standalone medical technology firm has spent the last 24 months aggressively shedding its "legacy" [...]
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, well below the S&P 500’s 11.2% gain. This may have investors wondering how to approach the situation.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Abbott Laboratories (ABT) is a top dividend stock with a strong history of increases, backed by exceptional earnings power and a very healthy balance sheet for reliable income.
New York, NY – December 9, 2025 – Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share. This declaration, coming on the heels of a consistently strong financial performance, reaffirms the company's
